We found that treatment of Siglec-10 Fc or pembrolizumab in monotherapy groups can promote CD45− Epcam+ tumor cell death and inhibit the proliferation of tumor cells compared to the isotype control (Fig. 7c, d). The gene discussed is EPCAM; the disease is neoplasm.